AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 203 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $548,179 | -8.9% | 23,865 | +11.4% | 0.03% | -17.5% |
| Q4 2022 | $601,754 | -0.7% | 21,430 | +0.1% | 0.04% | 0.0% |
| Q3 2022 | $606,000 | +1.5% | 21,411 | -20.5% | 0.04% | +25.0% |
| Q2 2022 | $597,000 | -7.3% | 26,940 | +21.7% | 0.03% | -5.9% |
| Q1 2022 | $644,000 | +4.4% | 22,138 | +18.0% | 0.03% | -8.1% |
| Q4 2021 | $617,000 | -56.2% | 18,756 | -38.5% | 0.04% | -53.2% |
| Q3 2021 | $1,408,000 | +30.6% | 30,512 | +56.0% | 0.08% | +36.2% |
| Q2 2021 | $1,078,000 | +41.1% | 19,565 | +32.2% | 0.06% | +31.8% |
| Q1 2021 | $764,000 | +4.2% | 14,800 | -12.5% | 0.04% | -17.0% |
| Q4 2020 | $733,000 | -60.7% | 16,908 | -68.3% | 0.05% | -13.1% |
| Q3 2020 | $1,867,000 | +13.4% | 53,349 | +73.2% | 0.06% | +45.2% |
| Q2 2020 | $1,647,000 | +688.0% | 30,801 | +424.0% | 0.04% | +600.0% |
| Q1 2020 | $209,000 | -40.3% | 5,878 | -45.5% | 0.01% | +50.0% |
| Q3 2019 | $350,000 | – | 10,790 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |